Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82
Status:
Completed
Trial end date:
2018-07-02
Target enrollment:
Participant gender:
Summary
In this this investigation, 15 subjects with a high probability of cardiac sarcoidosis based
on clinical criteria and abnormal cardiac FDG uptake on initial, clinically indicted FDG PET
study will be considered for this study. The study will test the following Aims:
Aim 1. Effect of FDG incubation time on visual and quantitative interpretation of FDG uptake.
Changes in incubation time can affect imaging target:background ratios and study
sensitivity/specificity. For the study-directed exam, all patients will undergo sequential
cardiacfocused FDG-PET imaging at 90 and 120 minutes after injection of FDG. Imaging
variables will be evaluated as below.
Aim 2. Reproducibility of FDG and Rb82 PET findings on sequential imaging. It is unknown
whether FDG-positive imaging findings in cardiac sarcoidosis are reproducible. All patients
will undergo study-directed FDG-PET/CT with MPI imaging within approximately 2 weeks from
initial clinical scan.